Notes on Chapter 5: Catecholamines

Chapter 5: Catecholamines

Overview

  • Main Focus: Understanding catecholamine synthesis, release, inactivation, and their related systems.   - Catecholamines include:     - Dopamine (DA)     - Norepinephrine (NE)     - Epinephrine (Epi)
  • Conceptual Framework:   - Neurotransmitter Lifecycle:     - Function/Organization     - Synthesis     - Packaging/Storage     - Release     - Inactivation

Introduction

  • Significance of Abnormal Function Studies:   - Provides insight into normal functions.   - Must maintain professionalism and empathy in discussions.
  • Example Study: Dopamine-deficient mouse model by Richard Palmiter, UW Biochemistry.   - Key Findings:     - Dopamine-deficient mice are:       - Severely hypoactive       - Adipsic (lack of thirst)       - Aphagic (lack of hunger)   - Original Model: Inactivating tyrosine hydroxylase (TH) gene and restoring TH function ameliorated conditions with L-DOPA administration.
  • Bottom Line: Fundamentals of the catecholamine system illuminate the outcomes observed in the model.

Catecholamine Synthesis

  • Precursor: Tyrosine from dietary protein.
  • Rate-limiting enzyme: Tyrosine hydroxylase (TH).
  • Synthesis Pathway:   - Tyrosine to DOPA conversion is slower than other steps.   - TH activity regulated by:     - Levels of DA and NE (high amounts in terminals reduce activity).     - Rate of cell firing via second messengers.
  • Modification Strategies:   - Increase synthesis rate using biological precursors such as L-DOPA.   - Decrease synthesis rate by enzyme inhibition (e.g., AMPT).

Catecholamine Storage and Release

  • Vesicular Packaging: Protects NT from degradation by enzymes.   - Transport facilitated by:     - Vesicular Monoamine Transporter (VMAT):       - VMAT1 present in adrenal medulla.       - VMAT2 present in the brain.       - Blockage: Reserpine blocks VMAT, leading to decreased catecholamine levels due to heightened breakdown by metabolizing enzymes.
  • Historical Context:   - Arvid Carlsson (1957): Proposed the catecholamine theory of depression.

Catecholamine Release Mechanisms

  • Autoreceptors:   - Located on dopaminergic neurons.   - Inhibit release through voltage-gated channels.   - Example: Clonidine stimulates NE autoreceptors.   - Drugs like amphetamine and methamphetamine induce release of catecholamines regardless of cell firing and block reuptake:     - Result in behavioral activation and stereotyped behaviors.
  • Neurodegenerative Observations: DA axon terminals in the striatum exhibit changes during degeneration.

Catecholamine Inactivation

  • Reuptake Mechanisms:   - Non-selective reuptake:     - DA transporter - impacts rodent behavior in response to psychostimulants.     - NE transporter - genetic deletion increases sensitivity to psychostimulants.     - ADHD medications target reuptake (e.g., methylphenidate (Ritalin), amphetamines (Adderall), tricyclic antidepressants).
  • Metabolic Breakdown:   - Enzymatic breakdown by:     - Catechol-O-methyltransferase (COMT): Generates metabolites like homovanillic acid (HVA) from DA and MHPG/VMA from NE.     - Monoamine Oxidase (MAO): Divided into MAO-A and MAO-B.   - Clinical Implications of Inactivation:     - MAO Inhibitors (MAOIs) used in clinical depression (e.g., phenelzine, tranylcypromine).     - Selective MAO-B inhibitors used for Parkinson's disease (e.g., selegiline, rasagiline).     - COMT inhibitors administered alongside L-DOPA for Parkinson's.

Organization & Function of the Dopaminergic System

  • Ascending DA System Structure: Originates in brain stem cell groups:   - Nigrostriatal tract   - Mesolimbic pathway   - Mesocortical pathway   - Tuberoinfundibular pathway
  • Functions of Dopamine:   - Influenced by evidence from various methodologies (clinical cases, animal studies).   - Dopamine-deficient mouse model details:     - Results in aphagia, adipsia, and hypoactivity normalized by L-DOPA.   - Significance of Dorsal Striatum: Critical in regulating behaviors, motivation, and cognition.

Functions of Dopamine

  • Movement Implication:   - Associated with Parkinson’s disease symptoms.   - Other mutations in DA genes lead to Parkinsonian symptoms (e.g., Segawa’s disease, loss-of-function mutations in DA transporter).   - MPTP as a DA neurotoxin causing neurodegeneration.
  • Striatum Region Segmentation:   - Ventral: Nucleus accumbens involvement in emotional and reward circuits.   - Dorsal: Caudate nucleus and putamen regulating behavior, attention, and cognitive function via mesocortical pathways.   - Activation by aversive stimuli leading to behavioral arousal and locomotion.

Notable Receptor Subtypes in Dopamine Function

  • Dopamine Receptor Types & Functions:   - D1 Receptor: G-protein coupled, facilitates neuronal growth and developing behavioral responses in basal ganglia.   - D2 Receptor: Functions as autoreceptors to modulate responses.   - α2 Receptor: Functions in modulation of symptoms like withdrawal; antagonism leads to heightened anxiety.   - Behavioral Activation and Medication Relationships:     - Drugs like apomorphine target D1 and D2 receptors to influence behavior, inhibition at high doses or antagonist treatments leading to catalepsy.

Dopamine Receptor Subtypes & Experimental Usage

  • Gene Manipulation Models:   - Gene knockout, knockin, overexpression, and transgenic animals used to study receptor functions and implications.
  • Figure Studies:   - D1 receptor knockout mice show diminished responsiveness to psychostimulants (e.g., cocaine).

Drugs Affecting the Dopaminergic System

DrugMechanism of Action
L-DOPADopamine precursor
CarbidopaPeripheral AADC inhibitor
MAO inhibitorsAntidepressants affecting dopamine and serotonin
AmphetaminesCatecholamine releaser and reuptake blocker
CocaineBlock DA, NE, 5-HT reuptake
HaloperidolD2 receptor antagonist (antipsychotic)

Organization & Function of the Noradrenergic System

  • Components: Central (CNS) and peripheral (PNS).
  • Locus Coeruleus (LC): Central site containing noradrenergic neurons.   - Sends projections across the forebrain and into the cerebellum and spinal cord.

Norepinephrine Function & Receptor Subtypes

  • Central Nervous System Functions:   - Modulates sensory input for goal-directed behaviors.
  • Adrenergic Receptors:   - Divided into alpha (α) and beta (β) subtypes involved in arousal and cognitive processes.
  • Inverted U-Shaped Relationship:   - NE in the PFC enhances attention and working memory performance non-stressfully within limitations of receptor affinity.

Norepinephrine and Stress Response

  • Panic Circuit Dynamics:   - Amygdala's role in interpreting fear/stress and activating LC for norepinephrine release, facilitating sympathetic activation.
  • Panic Disorder Characteristics:   - Dysfunction in NE feedback mechanisms leads to increased severity of panic symptoms.
  • Medication Classes:   - α2-agonists (e.g., clonidine) vs α2-antagonists (e.g., yohimbine) - effects on anxiety management.

Norepinephrine Medications

DrugMechanism of Action
Phenelzine/tranylcypromineNonselective MAO inhibitors
AtomoxetineSelective NE reuptake blocker (ADHD treatment)
Clonidineα2-agonist for hypertension, anxiety
PropranololNonselective β-receptor antagonist (anxiety)

Review Questions & Learning Objectives

  • Key Concepts to Explore:   - Understanding reversible vs irreversible inhibitors of catecholamine vesicular uptake.   - Comparison between DA-targeting methodologies (genetic engineering vs neurotoxins).   - Examining inverted U-shape relationship for NE in cognitive function and associated receptor implications.   - Mechanisms underlying enhanced consolidation of emotional memories and the role of involved neural circuitry and biochemical processes.